Literature DB >> 1798713

[Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice].

H Weber1, R Amlacher, R Preiss, H Hoffmann.   

Abstract

The pharmacokinetics of bendamustine, (1; Cytostasan), an alkylating antineoplastic agent of the N-lost group, was investigated in B6D2F1 mice. After i.v. injection of the maximally tolerated dose of 50 mg/kg a rapid decrease of the unchanged drug in plasma (MRT 21.9 min) and slowly decreasing levels of mono-, dihydroxy and beta-hydroxy-1 were observed. Variations of the age of the animals as well as of the dose administered did not alter the short MRT of 1. 1 is excreted via the kidneys to a considerable extent showing a similar metabolite pattern in urine as in plasma. The absorption of the drug from the gastrointestinal tract is incomplete resulting in an absolute bioavailability of about 40%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1798713

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  3 in total

1.  Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.

Authors:  Varsha Gandhi; Jan A Burger
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 2.  Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites.

Authors:  Mona Darwish; Mary Bond; Edward Hellriegel; Philmore Robertson; James P Chovan
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-01       Impact factor: 3.333

3.  A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.

Authors:  M Rasschaert; D Schrijvers; J Van den Brande; J Dyck; J Bosmans; K Merkle; J B Vermorken
Journal:  Br J Cancer       Date:  2007-05-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.